DDInter875 DDInter1926
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy [FDA label]. Previously, this drug was indicated only for patients with 17p gene deletion .
Venetoclax {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Venetoclax {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secobarbital
Venetoclax {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Venetoclax {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Venetoclax {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Venetoclax may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Venetoclax may lead to a major life threatening interaction when taken with Atazanavir
Venetoclax may lead to a major life threatening interaction when taken with Lorlatinib